Dr. Pavlick on the IGNYTE Trial in Patients With Melanoma Following Anti–PD-1 Progression
March 8th 2023
Anna C. Pavlick, DO, discusses the phase 2 IGNYTE trial examining vusolimogene oderparepvec in combination with nivolumab in 3 tumor-specific cohorts, including 1 featuring patients with anti–PD-1–failed cutaneous melanoma.